Efficacy and safety of an innate allogeneic haematopoietic stem cells transplantation in patients with haematological malignancies

Phase 2

Recruiting

• Conditions: blood cancer; lymphoma; 10024324

• Registration Number: NL-OMON44165
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

-Adults
-Haematological malignancies eligible to allo-SCT
-WHO performance status * 2
-Written informed consent

Exclusion Criteria

-Relapse of allo-SCT within 6 months after allo-SCT
-Bilirubin and/or transaminases > 2.5 x normal value
-Creatinine clearance < 40 ml/min
-Cardiac dysfunction as defined by (Unstable angina; Unstable cardiac arrhythmias)
-Active, uncontrolled infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Transplantation related mortality within 100 days. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Feasibility of 'low dose DLI' at 100 days; engraftment, toxicity in terms of<br /><br>incidence of GVHD and infectious complications, chance of relapse. </p><br>